# Epigenome and three-dimensional genome architecture remodeling during NDM29-mediated retro-transformation of neuroblastoma cells

**Authors:** Francesca Baldini, Aldo Pagano, Lama Zeaiter, Paolo Bianchini, Hawraa Zbeeb, Alberto Diaspro, Laura Vergani

PMC · DOI: 10.1371/journal.pone.0327466 · PLOS One · 2025-07-31

## TL;DR

This study explores how overexpressing the ncRNA NDM29 changes the nuclear structure and epigenetics of neuroblastoma cells, leading to a less malignant neuron-like state.

## Contribution

The study reveals novel nuclear and epigenetic changes during NDM29-mediated retro-transformation of neuroblastoma cells.

## Key findings

- NDM29 overexpression leads to smaller, more elongated nuclei and chromatin redistribution in neuroblastoma cells.
- Neuron-like cells show increased DNA methylation and upregulation of KAT2A and DNMT1.
- NF-κB-regulated genes are downregulated in NDM29-induced neuron-like cells.

## Abstract

Neoplastic transformation of mammalian cells involves intricate interactions between genetic, epigenetic and architecture modifications of the nucleus. Neuroblastoma is a malignant pediatric tumor with high biological and clinical heterogeneity representing a challenging model of study. We aimed to explore the changes in genome architecture and epigenetics being associated with neuroblastoma malignancy. We employed the neuroblastoma cell line SKNBE2 overexpressing the ncRNA NDM29 to differentiate from highly malignant into neuron-like cells. By 3D confocal microscopy, we explored the nuclear architecture (volume, elongation, compactness, and chromatin density). Using super-resolution microscopy (STED) and histone H3 immunolabelling we assessed the epigenetic rearrangement, and by enzyme-linked immunoassay the global DNA methylation. Then we assessed the mRNA expression of the main epigenetic modifying enzymes by quantitative PCR, and the expression of NF-κB-regulated genes by cDNA microarray. Compared to malignant NB cells, the NDM29-overexpressing cells, assuming a neuron-like phenotype, exhibited smaller and more elongated nuclei, redistribution of H3K9-acetylated and -methylated chromatin domains and DNA hypermethylation. In line with these results, in neuron-like cells the acetyltransferase KAT2A and the DNA methyltransferase DNMT1 were up-regulated, while most of NF-κB-regulated genes were down-regulated. Our findings reveal modifications of the nuclear structure and epigenome during neuroblastoma retro-transformation induced by NDM29 overexpression, with impacts on gene expression. These results offer potential insights into better understanding the mechanism of neuroblastoma malignancy in terms of chromatin rearrangements, opening exciting prospects for prognostic and therapeutic approaches with a focus on the nuclear level.

## Linked entities

- **Genes:** KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648], DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786], NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790]
- **Proteins:** KAT2A (lysine acetyltransferase 2A), DNMT1 (DNA methyltransferase 1)
- **Diseases:** neuroblastoma (MONDO:0005072)

## Full-text entities

- **Genes:** TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, GAPDH (glyceraldehyde-3-phosphate dehydrogenase) [NCBI Gene 2597] {aka G3PD, GAPD, HEL-S-162eP}, IRF1 (interferon regulatory factor 1) [NCBI Gene 3659] {aka IMD117, IRF-1, MAR}, MYB (MYB proto-oncogene, transcription factor) [NCBI Gene 4602] {aka Cmyb, c-myb, c-myb_CDS, efg}, CDT1 (chromatin licensing and DNA replication factor 1) [NCBI Gene 81620] {aka DUP, RIS2}, EHMT1 (euchromatic histone lysine methyltransferase 1) [NCBI Gene 79813] {aka EHMT1-IT1, EUHMTASE1, Eu-HMTase1, FP13812, GLP, GLP1}, TNFRSF1A (TNF receptor superfamily member 1A) [NCBI Gene 7132] {aka CD120a, FPF, TBP1, TNF-R, TNF-R-I, TNF-R55}, MYC (MYC proto-oncogene, bHLH transcription factor) [NCBI Gene 4609] {aka MRTL, MYCC, bHLHe39, c-Myc}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, CXCL8 (C-X-C motif chemokine ligand 8) [NCBI Gene 3576] {aka GCP-1, GCP1, IL8, LECT, LUCT, LYNAP}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}, EHMT2 (euchromatic histone lysine methyltransferase 2) [NCBI Gene 10919] {aka BAT8, C6orf30, G9A, GAT8, KMT1C, NG36}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, VCAM1 (vascular cell adhesion molecule 1) [NCBI Gene 7412] {aka CD106, INCAM-100}, ABCB1 (ATP binding cassette subfamily B member 1) [NCBI Gene 5243] {aka ABC20, CD243, CLCS, ENPAT, GP170, MDR1}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, MYCN (MYCN proto-oncogene, bHLH transcription factor) [NCBI Gene 4613] {aka FGLDS1, MODED, MPAPA, MYCNsORF, MYCNsPEP, N-myc}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, VEGFC (vascular endothelial growth factor C) [NCBI Gene 7424] {aka Flt4-L, LMPH1D, LMPHM4, VRP}, IFNB1 (interferon beta 1) [NCBI Gene 3456] {aka IFB, IFF, IFN-beta, IFNB}, TUBB3 (tubulin beta 3 class III) [NCBI Gene 10381] {aka CDCBM, CDCBM1, CFEOM3, CFEOM3A, FEOM3, TUBB4}, KAT2A (lysine acetyltransferase 2A) [NCBI Gene 2648] {aka GCN5, GCN5L2, PCAF-b, hGCN5}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, PRDM9 (PR/SET domain 9) [NCBI Gene 56979] {aka KMT8B, MEISETZ, MSBP3, PFM6, ZNF899}, DNMT1 (DNA methyltransferase 1) [NCBI Gene 1786] {aka ADCADN, AIM, CXXC9, DNMT, HSN1E, MCMT}
- **Diseases:** Neoplastic (MESH:D009369), NB (MESH:D009447), inflammation (MESH:D007249), infections (MESH:D007239), metastasis (MESH:D009362), nervous system tumors (MESH:D009423), tumorigenic (MESH:D002471), oncogenesis (MESH:D063646), embryonal tumor (MESH:D009373)
- **Chemicals:** CO2 (MESH:D002245), L-glutamine (MESH:D005973), Hoechst 33342 (MESH:C017807), oil (MESH:D009821), 5-mC (-), oligonucleotides (MESH:D009841), streptomycin (MESH:D013307), puromycin (MESH:D011691), cisplatin (MESH:D002945), G418 (MESH:C010680), silica (MESH:D012822), Trizol (MESH:C411644), 5-methylcytosine (MESH:D044503), penicillin (MESH:D010406), Alexa Fluor 546 (MESH:C481052), paraformaldehyde (MESH:C003043), doxorubicin (MESH:D004317)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Cell lines:** Mock — Homo sapiens (Human), Blast phase chronic myelogenous leukemia, BCR-ABL1 positive, Cancer cell line (CVCL_C0UQ), SKNBE2 — Homo sapiens (Human), Neuroblastoma, Cancer cell line (CVCL_0528), S1.1 — Gallus gallus (Chicken), Chicken bursal lymphoma, Cancer cell line (CVCL_1T28)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12312970/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12312970/full.md

## References

59 references — full list in the complete paper: https://tomesphere.com/paper/PMC12312970/full.md

---
Source: https://tomesphere.com/paper/PMC12312970